Analysis of 137,451 FDA adverse event reports spanning 13 years reveals GLP-1 receptor agonists produce markedly different side effect patterns depending on their prescribed use. When used for diabetes management, these medications showed unexpected associations with retinopathy, hearing loss, and cataracts. However, when prescribed for weight management, psychiatric and metabolic disturbances dominated the adverse event profile, alongside the well-known gastrointestinal effects. This indication-specific safety divergence represents a crucial clinical insight that challenges the assumption that drug safety profiles remain constant across different patient populations. The finding suggests metabolic context fundamentally alters how these medications interact with physiological systems. For the millions now using semaglutide, liraglutide, and related compounds, this data underscores the critical importance of tailored monitoring protocols. Clinicians treating diabetic patients should prioritize ophthalmologic and audiologic assessments, while those prescribing for weight loss should focus on psychological wellbeing and metabolic parameters. Given the explosive growth in GLP-1 prescribing—particularly off-label for weight management—these real-world safety patterns provide essential guidance for risk-benefit calculations in an era where long-term safety data remains limited for many newer applications.